{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.6","upperLimit":"14.1","value":"12.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"}],"units":"Participants"}],"description":"The OS is defined as the time from the start of study treatment until death due to any cause. The OS was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IV tisotumab vedotin 2.0 mg/kg Q3W until radiographic disease progression verified by the IRC, unacceptable AEs requiring drug discontinuation, withdrawal of consent, lost to follow up or death, whichever occurred first.","id":"OG000","title":"Tisotumab Vedotin"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants who received at least 1 dose of tisotumab vedotin.","reportingStatus":"POSTED","timeFrame":"From Day 1 until death or withdrawal from the study, whichever occurred first (approximately 49 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}